# Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

> **NCT06176235** · PHASE2 · WITHDRAWN · sponsor: **Peking University People's Hospital**

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Teriflunomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06176235
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-12-19
- **Primary completion:** 2024-12-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial withdrawn due to substantial protocol amendments invalidating the original design. With no participants enrolled, this aligns with WHO-ICTRP guidelines. Recruitment has ceased, and the revised protocol has been re-registered as NCT07065968.
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176235, "Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06176235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*